[Transferrin conjugates in the anticancer therapy].
To enhance the therapeutic efficiacy of anticancer drugs and reducing its systemic side-effects carriers are used. Transferrin is one of the very promising protein which can be used to transport drugs, DNA and ions into the cancer cells. Because of the fact that neoplastic cells have increased number of transferrin receptors, the transferrin can deliver the drugs directly to the neoplastic cells without injury of normal cells.
Lubgan
Dorota
D
Katedra Termobiologii, Uniwersytet Lódzki, Lódź. lubgan1@poczta.onet.pl
Marczak
Agnieszka
A
Distel
Luitpold
L
Jóźwiak
Zofia
Z
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004247:DNA / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000378:metabolism; D004337:Drug Carriers / Q000378:metabolism / Q000494:pharmacology*; D016503:Drug Delivery Systems; D004705:Endocytosis / Q000502:physiology; D006801:Humans; D007501:Iron / Q000378:metabolism; D008081:Liposomes / Q000493:pharmacokinetics; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D011990:Receptors, Transferrin / Q000187:drug effects / Q000378:metabolism*; D014168:Transferrin / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D004364:Pharmaceutical Preparations; D011990:Receptors, Transferrin; D014168:Transferrin; D004317:Doxorubicin; D004247:DNA; D007501:Iron